Piper ups Array BioPharma price target to $25 after early BRAF-melanoma approvalPiper Jaffray analyst Edward Tenthoff said he is encouraged by the early approval of Array Biopharma's Braftovi and Mektovi combination in BRAF-mutant melanoma ahead of the June 30 PDUFA date and he believes the label "looks good." Tenthoff, who thinks the improved tolerability and "best in class" efficacy of the combination will support rapid uptake, raised his price target on Array shares to $25 from $21 following the approval announcement and he keeps an Overweight rating on the stock. Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. $ARRY, Array BioPharma Inc. / M30 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.